ADMA - NASDAQ
ADMA Biologics, Inc.
$7.76
-1.8%ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
At a Glance
Live SnapshotADMA Biologics, Inc. Management Team
Mr. Brad Tade
Chief Financial Officer & Treasurer
Compensation
$680,951
Ms. Kaitlin Kestenberg
Chief Operating Officer & Senior Vice President of Compliance
Compensation
$815,808
Dr. Jerrold B. Grossman D.P.S., Ph.D.
Co-Founder & Vice Chairman of the Board
Compensation
$90,000
Mr. Adam S. Grossman
Co-Founder, President, Chief Executive Officer & Director
Compensation
$1,864,729
Mr. John Hafl
Executive Director of Sales
Mr. Michael Goldstein
General Counsel
Mr. Skyler Bloom
Senior Director of Business Development & Corporate Strategy
Ms. Cindy Petersen
Vice President of Human Resources
Mr. Drew Pantello
Vice President of Marketing & Corporate Development
ADMA Biologics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $468K and sold $11.16M worth of ADMA shares, resulting in $10.69M of net selling activity.
3 Months
38.4K
358.60K
25.1K
385.20K
-27K
-$27K
3-6 Months
7.0K
109.69K
30.0K
538.05K
-428K
-$428K
6-9 Months
0
0.00
27.0K
432.78K
-433K
-$433K
9-12 Months
0
0.00
473.6K
9.80M
-9.8M
-$9.80M
Top Buyers
Grossman Jerrold B
Director
$251K
Elms Steve
Director
$217K
Top Sellers
Elms Steve
Director
$8.83M
Grossman Adam S
Director, Officer: President And Ceo
$1.54M
Guiheen Lawrence P.
Director
$419K
Grossman Jerrold B
Director
$213K
Kestenberg-Messina Kaitlin M.
Officer: Coo And Svp, Compliance
$158K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $10.69M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Negative recent trend with net selling. Insiders have reduced positions in recent months, which could signal caution.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
ADMA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 15, 2026 | June 02, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 15, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 15, 2024 | June 04, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 13, 2023 | June 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 21, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 07, 2021 | May 27, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 18, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | July 16, 2019 | August 23, 2019 | 2019 | |
DEF 14A DEF 14A 2019 N/A | April 24, 2019 | June 05, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 27, 2018 | June 22, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.